PathoVax is a new biotechnology company seeking to eradicate HPV disease and cancers. Join us in "Blazing the trail to complete protection"
PathoVax LLC is developing breakthrough vaccines against infectious diseases and cancers utilizing a Human Papillomavirus Virus-Like Particle (HPV VLP) platform that has been exclusively licensed from the Johns Hopkins University. This technology is generated by the same investigators responsible for existing HPV vaccines, and can be used to present other antigens to induce robust humoral or cellu
lar immune responses against multiple infectious agents and tumors. Our lead candidate (RGVax™) is a patented, universal HPV vaccine that targets all clinically-relevant HPVs while sidestepping uptake challenges to more than double a global market with over $2B in annual revenues
Here at PathoVax, we are blazing the trail to complete protection. Disclaimer: The information contained in these posts is not intended or implied to be a substitute for professional medical advice and is provided for educational purposes only. Readers are to seek full responsibility on how to use this information. Always seek the advice of a physician or medical professional before starting any new treatment or discontinuing any existing treatment. Readers are to talk to their healthcare provider about any questions they may have regarding their medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment, nor should it be used as a substitute for the care and knowledge your physician may/can provide you.
